Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder

Datos Bibliográficos

ID15519340
AutoresRuize Song (Zhongda Hospital Southeast University), Yachen Shi (0000-0003-2241-9227, Zhongda Hospital Southeast University), Xianrui Li (0000-0002-7452-5796, Xinxiang Medical University), Jianli Zhu (Xinxiang Medical University), Hongxing Zhang (0009-0008-5178-3021, Henan Psychiatric Hospital), Kun Li (0000-0001-5862-1959, Xinxiang Medical University), Wang Bi (0000-0002-3591-4764, Xinxiang Medical University), Haisan Zhang (Xinxiang Medical University), Yongfeng Yang (0000-0003-0358-0752, Henan Psychiatric Hospital), Lijuan Gao (0000-0003-3657-3698, Zhongda Hospital Southeast University), Yang Zhao (0000-0003-4913-8505, Nanjing Medical University, autor de correspondencia), Zhijun Zhang (0000-0001-5480-0888, Xinxiang Medical University, autor de correspondencia)
Año2021
Volumen12
Páginas678384-678384
Fecha de publicación2021-10-28
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaFrontiers in Psychiatry (JOURNAL)
Identificadores de la revistaISSN: 1664-0640 • E-ISSN: 1664-0640
EditorialFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2021.678384
PMID34777034
OpenAlexW3209171140
IdiomaEN
Citas recibidas1
Referencias citadas8

Background: The evaluation of treatment response to antidepressant therapy commonly depends on neuropsychologic assessments, as there are currently no suitable biomarkers. Previous research has identified a panel of increased proteins in patients with major depressive disorder (MDD), including antithrombin III (ATIII), as potential biomarkers of depression. Methods: A total of 90 MDD patients were recruited. Of these, 74 patients received occipital repetitive transcranial magnetic stimulation (rTMS) as individualized, standard, or sham treatment for 5 days, and underwent the complete procedure, including clinical assessments, blood collection, and protein measurement. Results: After treatment, ATIII was significantly decreased in both the individualized and standard groups (both p p = 0.024 and 0.023, respectively). Conclusion: Our study revealed a reduction in ATIII after occipital rTMS in MDD patients and a relationship between change in ATIII and therapeutic response. Taken together, these findings provide evidence for the potential of ATIII as a biomarker for the evaluation and prediction of antidepressive effects

Antidepressant · Antithrombin · Biomarker · Depression (economics · Hamilton Rating Scale for Depression · Major depressive disorder · Stimulation · Transcranial magnetic stimulation · Medicine · Stress Responses and Cortisol · Transcranial Magnetic Stimulation Studies · Tryptophan and brain disorders · Gastroenterology · Internal Medicine · Oncology